Get the Stockscreener App
10.20
6.25%
-0.68
After Hours:
10.22
0.02
+0.20%
Aligos Therapeutics Inc stock is traded at $10.20, with a volume of 48,314.
It is down -6.25% in the last 24 hours and up +37.19% over the past month.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$10.88
Open:
$10.71
24h Volume:
48,314
Relative Volume:
0.57
Market Cap:
$54.58M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-0.42
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
-10.05%
1M Performance:
+37.19%
6M Performance:
-5.64%
1Y Performance:
-27.30%
1-Day Range:
$10.10
$10.82
1-Week Range:
$10.10
$11.65
52-Week Range:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
10.20 | 74.45M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Real time scanner hits for Aligos Therapeutics Inc. explainedBull Run & Verified Technical Signals - Newser
What machine learning models say about Aligos Therapeutics Inc.Weekly Trend Report & Proven Capital Preservation Tips - Newser
Applying Elliott Wave Theory to Aligos Therapeutics Inc.Weekly Loss Report & Weekly Breakout Stock Alerts - Newser
How to integrate Aligos Therapeutics Inc. into portfolio analysis toolsJuly 2025 Trends & Free Weekly Chart Analysis and Trade Guides - Newser
Adage Capital Partners GP L.L.C. Has $3.84 Million Stock Position in Aligos Therapeutics, Inc. $ALGS - MarketBeat
Can momentum traders help lift Aligos Therapeutics Inc.Weekly Trend Report & Risk Adjusted Swing Trade Ideas - Newser
Quantitative breakdown of Aligos Therapeutics Inc. recent moveJuly 2025 News Drivers & Proven Capital Preservation Tips - Newser
ALGS: HC Wainwright Reiterates "Buy" Rating for Aligos Therapeutics | ALGS Stock News - GuruFocus
Is now a turning point for Aligos Therapeutics Inc.Stop Loss & Proven Capital Preservation Tips - Newser
Aligos Therapeutics Inc. stock trend outlook and recovery pathWeekly Volume Report & Real-Time Volume Analysis Alerts - Newser
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect? - MSN
News impact scoring models applied to Aligos Therapeutics Inc.July 2025 Spike Watch & Low Risk High Win Rate Picks - Newser
Can a trend reversal in Aligos Therapeutics Inc. lead to recovery2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser
Using economic indicators to assess Aligos Therapeutics Inc. potentialSwing Trade & AI Driven Stock Price Forecasts - Newser
Trexquant Investment LP Reduces Stock Holdings in Aligos Therapeutics, Inc. $ALGS - MarketBeat
Applying Wyckoff theory to Aligos Therapeutics Inc. stockWeekly Investment Summary & Accurate Trade Setup Notifications - Newser
What does recent volatility data suggest for Aligos Therapeutics Inc.July 2025 PostEarnings & Consistent Return Investment Signals - Newser
Reversal indicators forming on Aligos Therapeutics Inc. stockJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - Newser
Aligos Therapeutics Inc. stock momentum explainedWeekly Loss Report & AI Driven Price Predictions - Newser
Published on: 2025-09-12 00:59:14 - Newser
How hedge fund analytics apply to Aligos Therapeutics Inc. stockEarnings Beat & High Accuracy Buy Signal Tips - Newser
Will Aligos Therapeutics Inc. outperform the marketJuly 2025 Breakouts & Daily Volume Surge Signals - Newser
Alyeska Investment Group L.P. Takes Position in Aligos Therapeutics, Inc. $ALGS - MarketBeat
Risk vs reward if holding onto Aligos Therapeutics Inc.Weekly Risk Summary & Daily Technical Forecast Reports - Newser
Using AI based signals to follow Aligos Therapeutics Inc.Weekly Market Outlook & Accurate Entry/Exit Alerts - Newser
Will Aligos Therapeutics Inc. bounce back from current supportPortfolio Return Summary & AI Powered Trade Plan Recommendations - Newser
Published on: 2025-09-11 01:08:07 - Newser
what’s next for aligos therapeutics inc. stock price2025 Sector Review & Growth Focused Stock Pick Reports - Newser
Aligos Therapeutics identifies new PD-1/PD-L1 inhibitors for liver disorders - BioWorld MedTech
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Identifying reversal signals in Aligos Therapeutics Inc.2025 Stock Rankings & Daily Stock Momentum Reports - Newser
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection - Investing News Network
Smart tools for monitoring Aligos Therapeutics Inc.’s price actionLong Setup & Low Risk High Win Rate Picks - Newser
Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs - MSN
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs - Investing News Network
Key resistance and support levels for Aligos Therapeutics Inc.July 2025 Spike Watch & Low Risk Profit Maximizing Plans - Newser
Aligos Therapeutics Inc. stock outlook for YEAR2025 Year in Review & Weekly Top Gainers Alerts - Newser
Will Aligos Therapeutics Inc. continue its uptrendPortfolio Risk Summary & Low Drawdown Trading Techniques - Newser
Sector ETF performance correlation with Aligos Therapeutics Inc.Options Play & Daily Growth Stock Tips - Newser
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):